Latest Ratios: P/E Ratio 53.9x · EV/EBITDA 23.0x · ROE 3.2%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.5B | $11.0B | $13.8B | $13.6B | $17.7B | $23.5B | $16.1B | $10.8B | $8.8B | $8.1B | $5.8B |
| Enterprise Value | $15.1B | $13.5B | $15.9B | $16.8B | $21.9B | $28.0B | $17.9B | $12.9B | $10.5B | $9.9B | $6.4B |
| P/E Ratio → | 53.87 | 46.51 | 46.47 | — | 31.15 | 24.87 | 22.09 | 47.58 | 36.69 | 71.72 | 24.62 |
| P/S Ratio | 4.39 | 3.84 | 4.99 | 4.96 | 5.35 | 6.13 | 4.25 | 3.75 | 3.15 | 3.59 | 2.72 |
| P/B Ratio | 1.75 | 1.51 | 1.79 | 1.73 | 2.40 | 3.28 | 4.31 | 3.85 | 3.39 | 3.24 | 2.67 |
| P/FCF | 24.65 | 21.55 | 25.39 | 1377.54 | 29.84 | 17.71 | 19.41 | 38.37 | 40.23 | 32.51 | 18.04 |
| P/OCF | 21.53 | 18.83 | 21.89 | 149.48 | 26.08 | 16.63 | 18.03 | 29.79 | 28.17 | 28.10 | 16.41 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.74 | 5.78 | 6.11 | 6.60 | 7.32 | 4.73 | 4.47 | 3.78 | 4.39 | 3.04 |
| EV / EBITDA | 22.95 | 20.56 | 18.99 | 20.20 | 18.10 | 16.96 | 14.14 | 20.81 | 19.02 | 24.19 | 15.88 |
| EV / EBIT | 42.41 | 37.59 | 38.60 | 59.60 | 28.93 | 21.46 | 18.72 | 42.86 | 32.31 | 29.09 | 22.55 |
| EV / FCF | — | 26.66 | 29.39 | 1695.81 | 36.80 | 21.15 | 21.61 | 45.69 | 48.17 | 39.74 | 20.19 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.1% | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% | 44.8% | 45.0% | 45.6% | 46.0% |
| Operating Margin | 12.5% | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 27.0% | 14.1% | 13.4% | 13.5% | 14.4% |
| Net Profit Margin | 8.5% | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 5.0% | 11.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 3.2% | 3.2% | 3.8% | -1.6% | 7.8% | 17.3% | 22.2% | 8.4% | 9.4% | 4.9% | 11.0% |
| ROA | 2.0% | 2.0% | 2.3% | -0.9% | 3.9% | 8.2% | 10.0% | 3.6% | 4.0% | 2.2% | 5.5% |
| ROIC | 2.7% | 2.7% | 3.0% | 2.7% | 5.0% | 11.7% | 14.7% | 6.6% | 6.5% | 6.4% | 8.0% |
| ROCE | 3.2% | 3.2% | 3.4% | 3.2% | 5.9% | 13.3% | 16.9% | 7.4% | 7.2% | 6.9% | 8.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.48 | 0.48 | 0.43 | 0.52 | 0.62 | 0.72 | 0.59 | 0.80 | 0.73 | 0.80 | 0.49 |
| Debt / EBITDA | 5.34 | 5.34 | 3.97 | 4.89 | 3.80 | 3.12 | 1.75 | 3.64 | 3.43 | 4.90 | 2.58 |
| Net Debt / Equity | — | 0.36 | 0.28 | 0.40 | 0.56 | 0.64 | 0.49 | 0.73 | 0.67 | 0.72 | 0.32 |
| Net Debt / EBITDA | 3.94 | 3.94 | 2.58 | 3.79 | 3.43 | 2.76 | 1.44 | 3.33 | 3.14 | 4.40 | 1.69 |
| Debt / FCF | — | 5.11 | 3.99 | 318.27 | 6.97 | 3.44 | 2.19 | 7.32 | 7.94 | 7.23 | 2.15 |
| Interest Coverage | 3.91 | 3.91 | 4.28 | 2.85 | 7.27 | 12.79 | 19.23 | 4.73 | 4.85 | 7.75 | 6.88 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.68 | 1.68 | 3.60 | 2.07 | 2.13 | 2.01 | 1.36 | 1.80 | 1.60 | 1.26 | 1.97 |
| Quick Ratio | 1.40 | 1.40 | 3.03 | 1.77 | 1.87 | 1.66 | 1.04 | 1.33 | 1.16 | 0.89 | 1.56 |
| Cash Ratio | 0.69 | 0.69 | 1.78 | 1.11 | 0.29 | 0.50 | 0.24 | 0.25 | 0.21 | 0.21 | 0.60 |
| Asset Turnover | — | 0.23 | 0.22 | 0.20 | 0.23 | 0.26 | 0.48 | 0.44 | 0.46 | 0.37 | 0.49 |
| Inventory Turnover | 3.53 | 3.53 | 3.90 | 3.34 | 3.83 | 3.63 | 3.48 | 4.46 | 4.51 | 3.49 | 4.63 |
| Days Sales Outstanding | — | 95.17 | 83.78 | 83.97 | 67.54 | 67.51 | 111.46 | 91.79 | 83.13 | 89.32 | 73.43 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.1% | 0.2% | 0.3% | 0.4% | 0.4% | 0.5% |
| Payout Ratio | 13.6% | 13.6% | 11.6% | — | 6.2% | 3.4% | 4.3% | 13.6% | 13.0% | 27.2% | 13.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 2.1% | 2.2% | — | 3.2% | 4.0% | 4.5% | 2.1% | 2.7% | 1.4% | 4.1% |
| FCF Yield | 4.1% | 4.6% | 3.9% | 0.1% | 3.4% | 5.6% | 5.2% | 2.6% | 2.5% | 3.1% | 5.5% |
| Buyback Yield | 6.6% | 7.5% | 2.7% | 2.9% | 0.5% | 0.3% | 0.0% | 0.1% | 0.7% | 0.0% | 2.6% |
| Total Shareholder Yield | 6.8% | 7.8% | 2.9% | 3.1% | 0.7% | 0.4% | 0.2% | 0.3% | 1.0% | 0.4% | 3.2% |
| Shares Outstanding | — | $113M | $123M | $125M | $126M | $117M | $112M | $112M | $112M | $111M | $110M |
Newborn screening volume sensitivity
Based on current market data, Revvity trades at a 54.34x trailing P/E, which appears to price in significant future earnings expansion that may be difficult to reconcile with the company's current 10.7% operating margin and the ongoing integration of its post-divestiture business model.
The forward P/E of 21.55 suggests that investors are anticipating a substantial recovery in profitability as the company sheds legacy industrial costs. However, this valuation premium warrants caution, as it assumes a level of operational efficiency that has yet to be consistently demonstrated in the post-PerkinElmer era.
According to recent financial statements, Revvity's ROIC has languished at 0.6% as of 2026Q1, a figure that reflects the heavy burden of intangible assets and goodwill on the balance sheet following aggressive acquisition activity in the life sciences and diagnostics space.
The persistent gap between invested capital and returns suggests that the company is currently struggling to generate economic profit on its asset base. Investors should monitor whether the company can improve its asset turnover, which currently sits at a low 0.06, to drive better capital efficiency.
As reported in quarterly filings, Revvity's cash conversion cycle reached 161 days in 2026Q1, indicating that the company's ability to efficiently manage its inventory and receivables has deteriorated compared to the 126-day cycle observed in 2025Q4, potentially signaling operational friction in the supply chain.
The elevated days sales outstanding and days inventory outstanding suggest that the company is carrying significant working capital, which may be a byproduct of the complex transition to a pure-play diagnostic entity. This inefficiency ties up liquidity that could otherwise be deployed toward higher-growth initiatives.
Based on reported figures, Revvity maintains a debt-to-EBITDA ratio of 18.52, which, while appearing high, is supported by an interest coverage ratio of 3.07, suggesting that the company's current debt service obligations remain manageable within its existing cash flow generation capacity.
While the leverage profile appears healthy, the high debt-to-EBITDA ratio highlights the sensitivity of the company's balance sheet to any potential earnings volatility. Investors should monitor the interest coverage ratio closely, as any further compression in operating margins could limit the company's financial flexibility.
The P/E ratio is frequently misapplied to Revvity because it fails to account for the significant non-cash amortization of intangibles resulting from the BioLegend acquisition, which artificially depresses reported net income and obscures the company's true underlying cash-generating potential.
Analysts should instead focus on EV/EBITDA or free cash flow yields to better assess the company's operational performance. Relying on P/E ratios in this context risks underestimating the company's earnings power by ignoring the high-margin, recurring nature of its reagent and software-driven business model.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RVTY stock.
Revvity, Inc.'s current P/E ratio is 53.9x. The historical average is 34.3x. This places it at the 88th percentile of its historical range.
Revvity, Inc.'s current EV/EBITDA is 23.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.9x.
Revvity, Inc.'s return on equity (ROE) is 3.2%. The historical average is 8.5%.
Based on historical data, Revvity, Inc. is trading at a P/E of 53.9x. This is at the 88th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Revvity, Inc.'s current dividend yield is 0.26% with a payout ratio of 13.6%.
Revvity, Inc. has 53.1% gross margin and 12.5% operating margin. Operating margin between 10-20% is typical for established companies.
Revvity, Inc.'s Debt/EBITDA ratio is 5.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.